Overview

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer. PURPOSE: This randomized phase III trial is studying how well dalteparin works in preventing blood clots in patients with lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Velindre NHS Trust
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin